Navigation Links
New Drug May Offer Hope to Some With Lung Cancer
Date:9/19/2009

Pemetrexed improves survival with advanced non-small-cell tumors, study finds,,

SATURDAY, Sept. 19 (HealthDay News) -- Maintenance therapy with the drug pemetrexed improves the survival of people with non-small-cell lung cancer whose disease has not progressed after chemotherapy, a new study has found.

Nearly 90 percent of all people who die from lung cancer have non-small-cell tumors. At the time the cancer is discovered, it's considered advanced about 40 percent of the time, according to background information in a news release from The Lancet, which is publishing the study. Chemotherapy reduces the tumors in just 40 percent of advanced cases, it said.

The phase 3 study included 663 people in 20 countries who had an advanced stage of the cancer but no disease progression after four cycles of platinum-based chemotherapy. They were randomly selected to be given pemetrexed or a placebo in 21-day cycles.

The cancers did not progress for 4.3 months, on average, in people in the pemetrexed group, compared with 2.6 months in the placebo group, the study found. People given pemetrexed survived an average of 13.4 months, compared with 10.6 months for those given the placebo.

That means that those in the pemetrexed group had a 50 percent reduction in the risk for disease progression or death and a 21 percent reduction in the risk of death only, the researchers said.

Drug-related toxic effects caused discontinuation of treatment in 5 percent of the pemetrexed group and 4 percent of the placebo group. No deaths were found to be related to pemetrexed, according to the study.

"Pemetrexed maintenance therapy is well tolerated and offers significantly improved progression-free and overall survival compared with placebo, making it a new treatment option for patients with advanced non-squamous, non-small-cell lung cancer who do not progress after initial induction therapy," Dr. Chandra Belani, of the Penn State Hershey Cancer Institute, and her colleagues concluded.

The study, which appears online and in an upcoming print issue of The Lancet, was released Sept. 19 to coincide with the European Cancer Organization meeting.

Dr. Thomas Stinchcombe of the Lineberger Comprehensive Cancer Center at the University of North Carolina, and Dr. Howard West, of the Swedish Cancer Institute in Seattle, wrote in an accompanying editorial that the use of pemetrexed as maintenance therapy "merits being considered as a strong option, reflected by the recent approval of pemetrexed in this setting by the European Medicines Agency and the U.S. Food and Drug Administration."

More information

The American Cancer Society has more about non-small-cell lung cancer.



-- Robert Preidt



SOURCE: The Lancet, news release, Sept. 19, 2009


'/>"/>
Copyright©2009 ScoutNews,LLC.
All rights reserved  

Related medicine news :

1. New prion protein discovered by Canadian scientists may offer insight into mad cow disease
2. Health care incentive model offers collaborative approach
3. Eye-staining technique offers early detection for dry eye syndrome
4. Governor Rendell Offers adultBasic Coverage to 35,000 Uninsured Pennsylvanians
5. Mylan Commences Tender Offers and Consent Solicitations for Its 5.750% Senior Notes Due 2010 and 6.375% Senior Notes Due 2015 in Connection With Its Proposed Acquisition of Mercks Generic Pharmaceutical Business
6. Psoriasis Cure Now offers Back to School Resources for Parents of Children with Psoriasis
7. ADDAS Awareness Campaign Offers Resources and Education to Adults Living with AD/HD and Professionals Working With Them
8. Consumers Offer to Pay More to Satisfy Health Demands
9. Regence Offers InterM to Fill Gap for the Uninsured
10. TriWest Creates First-of-its-Kind Partnership to Offer Military Leaders With Grief Support Program
11. Experimental Antidepressants Offer Faster Relief
Post Your Comments:
*Name:
*Comment:
*Email:
Related Image:
New Drug May Offer Hope to Some With Lung Cancer
(Date:1/24/2017)... ... January 24, 2017 , ... West’s Health Advocate Solutions, ... Series of webinars will start January 31 with a session about understanding healthcare ... health and benefits topics, including employee engagement, pricing transparency, population health and wellness, ...
(Date:1/24/2017)... Santa Margarita, CA (PRWEB) , ... January 24, 2017 , ... ... advancement platform for 21st century leadership, has named Hector M. Chavez, Manager, Employee & ... and diabetes treatment center - as its Hispanic Leader of the Month. City of ...
(Date:1/24/2017)... , ... January 24, 2017 , ... ... Need to Thrive , Well-meaning studies such as the Fordham Institute’s High ... better serve top students, such as including gifted or high-achieving students as a ...
(Date:1/24/2017)... , ... January 24, 2017 , ... American Family Care ... expanding access to high-quality health care for residents in the area. The Bedford clinic ... opened during the past four years by Dave Adams and Dr. Kristina Orio. Adams ...
(Date:1/24/2017)... ... ... “Speaking With God’s Voice”: a resolute and spirited call for anointed preaching ... A. Miraglia, a born-again believer, who spent his years teaching high school and Sunday-school, ... “There is little doubt that God Himself prepared me for this study, and God’s ...
Breaking Medicine News(10 mins):
(Date:1/24/2017)... and PUNE, India , January 24, ... by Allied Market Research, titled, "Cold Chain Logistics Market ... Dairy & Frozen Dessert, Meat, Fish & Sea Food, ... and Industry Forecasts, 2014-2022," projects that the global cold ... by 2022, growing at a CAGR of 16% (2016 ...
(Date:1/24/2017)... LONDON , January 24, 2017 Analysis ... End User Liquid Biopsies - our new study reveals ... biopsy market heading? If you are involved in this sector you ... you the potential revenues streams to 2027, assessing data, trends, opportunities ... ...
(Date:1/24/2017)... GAITHERSBURG, Md. , Jan. 24, 2017   ... in the engineering and industrialization of biology to improve the ... that it has entered into a definitive agreement to acquire ... clinical-stage company and pioneer in the development of AdenoVerse™ gene ... expand upon GenVec,s expertise in adenoviral vectors and cGMP drug ...
Breaking Medicine Technology: